SRSnezna Rogelj

Snezna Rogelj

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Snezna Rogelj has a total of 27 co-authors. Here are the top co-authors by number of shared publications:

  • Aleksander V. Aksenov

    Department of Chemistry, North Caucasus Federal University, 1a Pushkin St., 355017 Stavropol, Russia

    1 shared publication
  • Alexander Kornienko

    Texas State University

    1 shared publication
  • Alexander L. Pendleton

    School of Animal and Comparative Biomedical Sciences, University of Arizona, Tucson, AZ 85721, USA

    1 shared publication
  • Alexander N. Smirnov

    Department of Chemistry, North Caucasus Federal University, 1a Pushkin St., Stavropol 355009, Russian Federation

    1 shared publication
  • Andrew J. Brenner

    Cancer Therapy and Research Center, The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, Texas 78229, United States

    1 shared publication
  • Annelise De Carvalho

    Laboratoire de Cancérologie et de Toxicologie Expérimentale, Faculté de Pharmacie, Université Libre de Bruxelles (ULB), Campus de la Plaine, CP205/1, Boulevard du Triomphe, B-1050 Brussels, Belgium

    1 shared publication

Latest Publications

  • Activity of 2-Aryl-2-(3-indolyl)acetohydroxamates against Drug-Resistant Cancer Cells

    by Alexander V. Aksenov, Alexander N. Smirnov, Igor V. Magedov, Mary R. Reisenauer, Nicolai A. Aksenov, Inna V. Aksenova, Alexander L. Pendleton, Gina Nguyen, Robert K. Johnston, Michael Rubin, et al.

    Many types of tumor, including glioma, melanoma, non-small cell lung, esophageal, and head and neck cancer, among others, are intrinsically resistant to apoptosis induction and poorly responsive to current therapies with proapoptotic agents. In addition, tumors often develop multidrug resistance based on the cellular efflux of chemotherapeutic agents. Thus, novel anticancer agents capable of overcoming these intrinsic or developed tumor resistance mechanisms are urgently needed. We describe a series of 2-aryl-2-(3-indolyl)acetohydroxamic acids that are active against apoptosis- and multidrug-resistant cancer cells as well as glioblastoma neurosphere stemlike cell cultures derived from patients. Thus, the described compounds serve as a novel chemical scaffold for the development of potentially highly effective clinical cancer drugs.


  • Enzyme Destruction by a Protease Contaminant in Bacitracin

    by Snezna Rogelj, Kimberly J. Reiter, Leo Kesner, Mengru Li, David Essex


  • Open Access

    Sulfhydryl Regulation of L-Selectin Shedding: Phenylarsine Oxide Promotes Activation-Independent L-Selectin Shedding from Leukocytes

    by Teresa A Bennett, Bruce S. Edwards, Larry A Sklar, Snezna Rogelj

    The L-selectin adhesion molecule mediates leukocyte recruitment to inflammatory sites and lymphocyte trafficking through the peripheral lymph nodes. In response to leukocyte activation, L-selectin is proteolytically released from the cell surface, disabling leukocytes from the subsequent L-selectin-dependent interactions. We have found that L-selectin shedding is sensitive to sulfhydryl chemistry; it is promoted by thiol-oxidizing or -blocking reagents and inhibited by reducing reagents. Phenylarsine oxide (PAO), a trivalent arsenical that interacts with vicinal dithiols, is most potent in inducing rapid shedding of L-selectin from isolated neutrophils, eosinophils, and lymphocytes as well as from neutrophils in whole blood. PAO does not cause cell activation, nor does it interfere with integrin function or alter the expression of several other cell surface molecules at the low concentrations that induce L-selectin shedding. PAO is not required to enter the cell to induce L-selectin shedding. TAPI-2 ((N-{d,l-[2-(hydroxyaminocarbonyl)-methyl]-4-methylpentanoyl}-l-3-(tert-butyl)-alanyl-l-alanine, 2-aminoethyl amide), which has previously been shown to inhibit the activation-dependent L-selectin shedding, is also capable of inhibiting PAO-induced L-selectin shedding. We hypothesize that PAO-induced L-selectin shedding involves a regulatory molecule, such as protein disulfide isomerase (PDI), an enzyme that plays a role in the formation and rearrangement of disulfide bonds, contains PAO-binding, vicinal dithiol-active sites, and is expressed on the neutrophil surface. Cell surface expression of PDI, L-selectin shedding induced by PDI-blocking Abs and by bacitracin, a known inhibitor of PDI activity, and direct binding of PDI to PAO, provide supporting evidence for this hypothesis.